EyePoint Pharmaceuticals (EYPT) Financials

$7.00 -0.30 (-4.04%)

As of 11:35 AM Eastern

Annual Income Statements for EyePoint Pharmaceuticals

This table shows EyePoint Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-102	-71	-131
Consolidated Net Income / (Loss)	-102	-71	-131
Net Income / (Loss) Continuing Operations	-102	-71	-131
Total Pre-Tax Income	-102	-71	-131
Total Operating Income	-100	-75	-146
Total Gross Profit	33	46	43
Total Revenue	41	46	43
Operating Revenue	41	46	43
Total Cost of Revenue	8.33	0.00	0.00
Total Operating Expenses	133	121	189
Selling, General & Admin Expense	35	40	52
Marketing Expense	26	12	0.13
Research & Development Expense	50	65	133
Amortization Expense	2.05	0.00	0.00
Other Operating Expenses / (Income)	-	4.63	3.71
Impairment Charge	21	0.00	0.00
Total Other Income / (Expense), net	-2.62	4.36	15
Interest Expense	4.75	2.59	0.01
Other Income / (Expense), net	2.13	6.95	15
Income Tax Expense	0.00	0.08	0.09
Basic Earnings per Share	($2.74)	($1.82)	($2.32)
Weighted Average Basic Shares Outstanding	37.32M	38.90M	56.30M
Diluted Earnings per Share	($2.74)	($1.82)	($2.32)
Weighted Average Diluted Shares Outstanding	37.32M	38.90M	56.30M
Weighted Average Basic & Diluted Shares Outstanding	34.30M	49.83M	68.73M

This table shows EyePoint Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-18	-43	-21	-23	-13	-14	-29	-31	-29	-41
Consolidated Net Income / (Loss)	-18	-43	-21	-23	-13	-14	-29	-31	-29	-41
Net Income / (Loss) Continuing Operations	-18	-43	-21	-23	-13	-14	-29	-31	-29	-41
Total Pre-Tax Income	-18	-43	-21	-23	-13	-14	-29	-31	-29	-41
Total Operating Income	-18	-44	-22	-23	-14	-16	-33	-35	-33	-45
Total Gross Profit	10	3.98	7.04	7.31	14	18	11	8.08	9.79	14
Total Revenue	10	11	7.68	9.11	15	14	12	9.48	11	12
Operating Revenue	10	11	7.68	9.11	15	14	12	9.48	11	12
Total Cost of Revenue	0.00	6.55	0.64	1.79	1.20	-3.63	0.76	1.40	0.74	-2.90
Total Operating Expenses	28	48	29	30	28	34	44	43	43	60
Selling, General & Admin Expense	9.21	8.50	9.24	9.06	11	11	14	13	13	13
Marketing Expense	6.02	5.92	5.74	5.29	0.48	0.19	0.01	0.05	0.02	0.05
Research & Development Expense	11	16	14	16	17	18	30	30	30	43
Total Other Income / (Expense), net	-0.02	0.29	0.39	-0.16	1.79	2.34	4.04	3.72	3.39	3.93
Interest Expense	0.66	0.78	0.81	1.78	0.00	-	0.00	0.00	0.00	0.01
Other Income / (Expense), net	0.64	1.07	1.20	1.62	1.79	2.34	4.04	3.72	3.39	3.94
Basic Earnings per Share	($0.49)	($1.16)	($0.56)	($0.61)	($0.33)	($0.32)	($0.55)	($0.58)	($0.54)	($0.65)
Weighted Average Basic Shares Outstanding	37.34M	37.32M	37.49M	37.58M	38.34M	38.90M	52.91M	53.21M	54.45M	56.30M
Diluted Earnings per Share	($0.49)	($1.16)	($0.56)	($0.61)	($0.33)	($0.32)	($0.55)	($0.58)	($0.54)	($0.65)
Weighted Average Diluted Shares Outstanding	37.34M	37.32M	37.49M	37.58M	38.34M	38.90M	52.91M	53.21M	54.45M	56.30M
Weighted Average Basic & Diluted Shares Outstanding	34.08M	34.30M	34.30M	34.98M	35.31M	49.83M	52.08M	53.52M	68.25M	68.73M

This table details how cash moves in and out of EyePoint Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-83	186	-182
Net Cash From Operating Activities	-65	1.88	-126
Net Cash From Continuing Operating Activities	-65	1.88	-126
Net Income / (Loss) Continuing Operations	-102	-71	-131
Consolidated Net Income / (Loss)	-102	-71	-131
Depreciation Expense	0.40	0.46	1.54
Amortization Expense	1.49	-0.86	-5.95
Non-Cash Adjustments To Reconcile Net Income	38	14	37
Changes in Operating Assets and Liabilities, net	-3.09	59	-28
Net Cash From Investing Activities	-17	-3.32	-219
Net Cash From Continuing Investing Activities	-17	-3.32	-219
Purchase of Property, Plant & Equipment	-2.15	-3.48	-4.05
Purchase of Investments	-139	-55	-398
Sale and/or Maturity of Investments	124	55	183
Net Cash From Financing Activities	-0.69	187	164
Net Cash From Continuing Financing Activities	-0.69	187	164
Repayment of Debt	-74	-47	0.00
Repurchase of Common Equity	-0.60	-0.45	-0.67
Issuance of Debt	74	5.30	0.00
Issuance of Common Equity	0.00	226	163
Other Financing Activities, net	-0.04	3.17	1.38
Effect of Exchange Rate Changes	0.00	0.00	0.00
Cash Interest Paid	2.60	1.41	0.00

This table details how cash moves in and out of EyePoint Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-6.77	20	10	34	-6.56	148	-10	-180	-11	20
Net Cash From Operating Activities	-13	-13	-17	57	-15	-23	-31	-20	-39	-36
Net Cash From Continuing Operating Activities	-13	-13	-17	57	-15	-23	-31	-20	-39	-36
Net Income / (Loss) Continuing Operations	-18	-43	-21	-23	-13	-14	-29	-31	-29	-41
Consolidated Net Income / (Loss)	-18	-43	-21	-23	-13	-14	-29	-31	-29	-41
Depreciation Expense	0.10	0.13	0.11	0.13	0.12	0.11	0.30	0.36	0.41	0.47
Amortization Expense	0.40	-0.14	-0.24	-0.05	-0.04	-0.52	-0.58	-1.69	-1.88	-1.81
Non-Cash Adjustments To Reconcile Net Income	3.20	26	3.24	3.64	4.10	3.12	13	8.70	7.45	7.90
Changes in Operating Assets and Liabilities, net	1.59	4.79	1.23	76	-6.76	-12	-14	3.28	-16	-1.01
Net Cash From Investing Activities	6.27	33	32	13	-1.72	-47	21	-160	16	-96
Net Cash From Continuing Investing Activities	6.27	33	32	13	-1.72	-47	21	-160	16	-96
Purchase of Property, Plant & Equipment	-1.20	-0.59	-0.48	-0.40	-1.72	-0.88	-1.19	-0.90	-1.57	-0.38
Purchase of Investments	-34	-13	-2.93	-2.92	-	-49	0.00	-185	-49	-164
Sale and/or Maturity of Investments	41	47	36	17	-	3.00	22	26	67	69
Net Cash From Financing Activities	0.09	-0.06	-5.12	-37	10	218	0.12	0.33	12	152
Net Cash From Continuing Financing Activities	0.09	-0.06	-5.12	-37	10	218	0.12	0.33	12	152
Repayment of Debt	-10	-11	-10	-37	-	-	0.00	-	-0.07	0.07
Repurchase of Common Equity	-0.03	-	0.00	-	-0.42	-0.04	-0.09	0.09	-0.31	-0.37
Issuance of Common Equity	-	-	-	-	9.97	216	-	-	12	152
Other Financing Activities, net	0.12	-0.06	0.06	-0.01	0.80	2.32	0.20	0.55	0.17	0.46

This table presents EyePoint Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	180	355	418
Total Current Assets	173	345	383
Cash & Equivalents	96	281	100
Short-Term Investments	49	50	271
Accounts Receivable	16	0.81	0.61
Inventories, net	2.89	3.91	2.31
Prepaid Expenses	9.86	9.04	9.48
Plant, Property, & Equipment, net	1.36	5.25	8.18
Total Noncurrent Assets	6.19	5.13	27
Intangible Assets	0.00	0.00	0.00
Other Noncurrent Operating Assets	6.04	4.98	27
Other Noncurrent Nonoperating Assets	0.15	0.15	0.15
Total Liabilities & Shareholders' Equity	180	355	418
Total Liabilities	84	89	82
Total Current Liabilities	35	63	49
Short-Term Debt	10	0.00	0.00
Accounts Payable	5.92	6.50	12
Accrued Expenses	16	18	18
Current Deferred Revenue	1.21	39	18
Other Current Liabilities	0.58	0.65	1.44
Total Noncurrent Liabilities	49	26	33
Long-Term Debt	29	0.00	0.00
Noncurrent Deferred Revenue	14	21	11
Other Noncurrent Operating Liabilities	6.58	4.91	22
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	96	266	337
Total Preferred & Common Equity	96	266	337
Preferred Stock	0.00	0.00	0.00
Total Common Equity	96	266	337
Common Stock	767	1,008	1,208
Retained Earnings	-671	-742	-873
Accumulated Other Comprehensive Income / (Loss)	0.79	0.86	1.03

This table presents EyePoint Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	220	155	176	160	329	324	301
Total Current Assets	192	146	167	150	318	295	269
Cash & Equivalents	75	106	140	133	271	91	80
Short-Term Investments	82	17	2.94	2.98	28	189	174
Accounts Receivable	21	10	11	0.48	3.02	1.38	0.38
Inventories, net	3.53	4.07	4.26	4.58	4.26	3.67	2.81
Prepaid Expenses	10	9.08	9.37	9.09	11	9.64	12
Plant, Property, & Equipment, net	1.02	2.61	2.87	4.48	6.68	6.90	8.39
Total Noncurrent Assets	27	5.93	5.66	5.40	4.86	22	24
Intangible Assets	21	0.00	0.00	0.00	0.00	0.00	0.00
Other Noncurrent Operating Assets	6.32	5.78	5.51	5.25	4.71	22	24
Other Noncurrent Nonoperating Assets	0.15	0.15	0.15	0.15	0.15	0.15	0.15
Total Liabilities & Shareholders' Equity	220	155	176	160	329	324	301
Total Liabilities	84	76	118	101	79	96	82
Total Current Liabilities	34	27	69	64	63	62	49
Short-Term Debt	10	5.30	0.00	0.00	0.00	0.00	0.00
Accounts Payable	6.11	9.45	11	9.58	7.08	14	7.34
Accrued Expenses	16	10	15	13	16	13	14
Current Deferred Revenue	1.17	1.24	42	40	38	33	26
Other Current Liabilities	0.50	0.77	0.97	1.06	1.18	1.13	1.29
Total Noncurrent Liabilities	50	49	49	38	17	34	33
Long-Term Debt	29	29	0.00	0.00	0.00	0.00	0.00
Noncurrent Deferred Revenue	14	13	44	32	12	12	11
Other Noncurrent Operating Liabilities	6.84	6.32	5.46	5.19	4.62	22	22
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	136	78	57	59	250	228	219
Total Preferred & Common Equity	136	78	57	59	250	228	219
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	136	78	57	59	250	228	219
Common Stock	764	770	772	786	1,021	1,030	1,049
Retained Earnings	-628	-693	-715	-728	-771	-802	-832
Accumulated Other Comprehensive Income / (Loss)	0.65	0.84	0.84	0.84	0.84	0.79	1.17

This table displays calculated financial ratios and metrics derived from EyePoint Pharmaceuticals' official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	12.09%	11.14%	-5.97%
EBITDA Growth	-85.36%	28.35%	-97.31%
EBIT Growth	-77.34%	30.14%	-91.97%
NOPAT Growth	-80.25%	24.66%	-94.30%
Net Income Growth	-75.04%	30.77%	-84.86%
EPS Growth	-34.98%	33.58%	-27.47%
Operating Cash Flow Growth	-29.76%	102.88%	-6,832.05%
Free Cash Flow Firm Growth	-42.46%	107.26%	-3,610.32%
Invested Capital Growth	-192.68%	-658.09%	46.73%
Revenue Q/Q Growth	-2.38%	8.22%	-5.34%
EBITDA Q/Q Growth	-36.36%	29.20%	-26.37%
EBIT Q/Q Growth	-33.79%	29.61%	-26.36%
NOPAT Q/Q Growth	-34.74%	26.73%	-24.69%
Net Income Q/Q Growth	-30.70%	29.31%	-26.36%
EPS Q/Q Growth	-30.48%	30.27%	-16.58%
Operating Cash Flow Q/Q Growth	5.91%	-84.87%	-11.23%
Free Cash Flow Firm Q/Q Growth	15.03%	-84.60%	-6.60%
Invested Capital Q/Q Growth	-145.85%	16.33%	1.84%
Profitability Metrics	-	-	-
Gross Margin	79.89%	100.00%	100.00%
EBITDA Margin	-230.94%	-148.88%	-312.39%
Operating Margin	-240.65%	-163.13%	-337.06%
EBIT Margin	-235.50%	-148.02%	-302.19%
Profit (Net Income) Margin	-246.97%	-153.84%	-302.43%
Tax Burden Percent	100.00%	100.12%	100.07%
Interest Burden Percent	104.87%	103.81%	100.01%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-20,634.88%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-20,611.67%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	20,562.04%	0.00%	0.00%
Return on Equity (ROE)	-72.84%	-39.04%	-43.42%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-43.95%	-25.44%	-33.81%
Return on Assets (ROA)	-46.09%	-26.44%	-33.83%
Return on Common Equity (ROCE)	-72.84%	-39.04%	-43.42%
Return on Equity Simple (ROE_SIMPLE)	-106.11%	-26.58%	-38.89%
Net Operating Profit after Tax (NOPAT)	-70	-53	-102
NOPAT Margin	-168.45%	-114.19%	-235.94%
Net Nonoperating Expense Percent (NNEP)	-23.21%	-8.37%	-8.19%
Return On Investment Capital (ROIC_SIMPLE)	-	-19.73%	-30.34%
Cost of Revenue to Revenue	20.11%	0.00%	0.00%
SG&A Expenses to Revenue	84.09%	87.14%	120.99%
R&D to Revenue	119.90%	140.51%	307.18%
Operating Expenses to Revenue	320.54%	263.13%	437.06%
Earnings before Interest and Taxes (EBIT)	-98	-68	-131
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-96	-69	-135
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.24	3.06	1.51
Price to Tangible Book Value (P/TBV)	1.24	3.06	1.51
Price to Revenue (P/Rev)	2.88	17.73	11.75
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.35	10.54	3.18
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	258.64	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	128.56	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.41	0.00	0.00
Long-Term Debt to Equity	0.30	0.00	0.00
Financial Leverage	-1.00	-1.20	-1.17
Leverage Ratio	1.58	1.48	1.28
Compound Leverage Factor	1.66	1.53	1.28
Debt to Total Capital	29.22%	0.00%	0.00%
Short-Term Debt to Total Capital	7.69%	0.00%	0.00%
Long-Term Debt to Total Capital	21.53%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	70.78%	100.00%	100.00%
Debt to EBITDA	-0.42	0.00	0.00
Net Debt to EBITDA	1.10	0.00	0.00
Long-Term Debt to EBITDA	-0.31	0.00	0.00
Debt to NOPAT	-0.57	0.00	0.00
Net Debt to NOPAT	1.50	0.00	0.00
Long-Term Debt to NOPAT	-0.42	0.00	0.00
Altman Z-Score	-4.99	3.03	0.83
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	5.00	5.45	7.81
Quick Ratio	4.63	5.25	7.57
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-52	3.77	-132
Operating Cash Flow to CapEx	-3,023.49%	53.83%	-3,115.15%
Free Cash Flow to Firm to Interest Expense	-10.94	1.45	-9,458.06
Operating Cash Flow to Interest Expense	-13.69	0.72	-9,016.14
Operating Cash Flow Less CapEx to Interest Expense	-14.14	-0.62	-9,305.57
Efficiency Ratios	-	-	-
Asset Turnover	0.19	0.17	0.11
Accounts Receivable Turnover	2.45	5.64	61.29
Inventory Turnover	2.56	0.00	0.00
Fixed Asset Turnover	45.10	13.92	6.45
Accounts Payable Turnover	1.25	0.00	0.00
Days Sales Outstanding (DSO)	149.23	64.67	5.96
Days Inventory Outstanding (DIO)	142.52	0.00	0.00
Days Payable Outstanding (DPO)	291.61	0.00	0.00
Cash Conversion Cycle (CCC)	0.14	64.67	5.96
Capital & Investment Metrics	-	-	-
Invested Capital	-8.56	-65	-35
Invested Capital Turnover	122.50	-1.25	-0.87
Increase / (Decrease) in Invested Capital	-18	-56	30
Enterprise Value (EV)	15	485	138
Market Capitalization	119	816	508
Book Value per Share	$2.83	$7.54	$4.93
Tangible Book Value per Share	$2.83	$7.54	$4.93
Total Capital	136	266	337
Total Debt	40	0.00	0.00
Total Long-Term Debt	29	0.00	0.00
Net Debt	-105	-331	-371
Capital Expenditures (CapEx)	2.15	3.48	4.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)	4.19	-50	-37
Debt-free Net Working Capital (DFNWC)	149	282	334
Net Working Capital (NWC)	138	282	334
Net Nonoperating Expense (NNE)	33	18	29
Net Nonoperating Obligations (NNO)	-105	-331	-371
Total Depreciation and Amortization (D&A)	1.89	-0.39	-4.41
Debt-free, Cash-free Net Working Capital to Revenue	10.11%	-107.59%	-84.71%
Debt-free Net Working Capital to Revenue	359.26%	611.80%	772.44%
Net Working Capital to Revenue	333.96%	611.80%	772.44%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($2.74)	($1.82)	($2.32)
Adjusted Weighted Average Basic Shares Outstanding	37.32M	38.90M	56.30M
Adjusted Diluted Earnings per Share	($2.74)	($1.82)	($2.32)
Adjusted Weighted Average Diluted Shares Outstanding	37.32M	38.90M	56.30M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	34.30M	49.83M	68.73M
Normalized Net Operating Profit after Tax (NOPAT)	-55	-53	-102
Normalized NOPAT Margin	-133.46%	-114.19%	-235.94%
Pre Tax Income Margin	-246.97%	-153.66%	-302.22%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-20.54	-26.26	-9,340.43
NOPAT to Interest Expense	-14.69	-20.26	-7,292.70
EBIT Less CapEx to Interest Expense	-20.99	-27.60	-9,629.86
NOPAT Less CapEx to Interest Expense	-15.14	-21.60	-7,582.13
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.59%	-0.64%	-0.51%

This table displays calculated financial ratios and metrics derived from EyePoint Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	10.52%	-8.76%	-17.33%	-21.27%	51.84%	33.18%	52.08%	4.09%	-30.77%	-17.39%
EBITDA Growth	-19.50%	-148.41%	-17.65%	-15.29%	27.37%	66.20%	-44.24%	-52.71%	-145.92%	-195.56%
EBIT Growth	-16.01%	-136.48%	-11.68%	-12.11%	28.98%	67.15%	-43.89%	-45.83%	-132.80%	-194.63%
NOPAT Growth	-20.15%	-142.33%	-17.88%	-18.45%	21.74%	62.61%	-54.59%	-51.78%	-127.45%	-176.62%
Net Income Growth	-10.33%	-123.61%	-0.90%	-18.11%	31.53%	67.55%	-38.37%	-34.49%	-132.80%	-193.63%
EPS Growth	15.52%	-70.59%	0.00%	-17.31%	32.65%	72.41%	1.79%	4.92%	-63.64%	-103.13%
Operating Cash Flow Growth	-68.69%	24.48%	16.48%	398.19%	-15.74%	-83.58%	-85.16%	-135.39%	-156.70%	-55.13%
Free Cash Flow Firm Growth	-334.58%	-23.21%	175.64%	600.08%	486.90%	449.86%	67.31%	-164.48%	-175.76%	-238.13%
Invested Capital Growth	101.07%	-192.68%	-161.92%	-533.51%	-515.39%	-658.09%	-417.48%	39.02%	54.59%	46.73%
Revenue Q/Q Growth	-13.43%	5.20%	-27.06%	18.51%	66.96%	-7.72%	-16.71%	-18.89%	11.05%	10.11%
EBITDA Q/Q Growth	5.49%	-147.24%	51.98%	-2.76%	40.47%	-15.08%	-104.88%	-8.80%	4.13%	-38.30%
EBIT Q/Q Growth	5.81%	-140.29%	52.30%	-3.86%	40.33%	-11.13%	-108.93%	-5.27%	4.75%	-40.65%
NOPAT Q/Q Growth	4.26%	-137.74%	50.72%	-5.60%	36.74%	-13.59%	-103.75%	-3.68%	5.20%	-38.14%
Net Income Q/Q Growth	5.08%	-135.90%	51.29%	-8.30%	44.97%	-11.79%	-107.70%	-5.27%	4.75%	-41.00%
EPS Q/Q Growth	5.77%	-136.73%	51.72%	-8.93%	45.90%	3.03%	-71.88%	-5.45%	6.90%	-20.37%
Operating Cash Flow Q/Q Growth	31.31%	4.17%	-33.74%	438.72%	-126.66%	-51.99%	-34.89%	35.27%	-93.42%	8.15%
Free Cash Flow Firm Q/Q Growth	-24.81%	42.39%	177.65%	795.70%	-3.44%	-47.90%	-62.87%	-445.18%	-13.46%	5.02%
Invested Capital Q/Q Growth	-5.27%	-145.85%	-11.92%	-791.87%	9.23%	16.33%	23.60%	-5.10%	32.41%	1.84%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	37.82%	91.67%	80.32%	92.09%	125.91%	93.50%	85.22%	93.01%	124.99%
EBITDA Margin	-172.40%	-405.16%	-266.71%	-231.27%	-82.46%	-102.84%	-252.96%	-339.31%	-292.94%	-367.95%
Operating Margin	-183.76%	-415.26%	-280.54%	-249.98%	-94.71%	-116.58%	-285.18%	-364.52%	-311.17%	-390.40%
EBIT Margin	-177.37%	-405.12%	-264.90%	-232.16%	-82.96%	-99.91%	-250.63%	-325.27%	-278.99%	-356.36%
Profit (Net Income) Margin	-183.98%	-412.53%	-275.47%	-251.73%	-82.96%	-100.51%	-250.63%	-325.27%	-278.99%	-357.26%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.59%	100.00%	100.00%	100.00%	100.22%
Interest Burden Percent	103.73%	101.83%	103.99%	108.43%	100.00%	100.00%	100.00%	100.00%	100.00%	100.03%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-390.39%	-35,607.41%	-2,653.48%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-384.88%	-35,598.25%	-2,648.41%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	337.92%	35,512.53%	2,584.79%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-52.47%	-94.88%	-68.69%	-101.57%	-102.73%	-39.04%	-48.07%	-60.81%	-74.68%	-43.42%
Cash Return on Invested Capital (CROIC)	-437.52%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-38.70%	-75.60%	-52.82%	-42.37%	-18.54%	-17.17%	-51.82%	-65.58%	-55.33%	-39.87%
Return on Assets (ROA)	-40.15%	-76.99%	-54.92%	-45.95%	-18.54%	-17.27%	-51.82%	-65.58%	-55.33%	-39.97%
Return on Common Equity (ROCE)	-52.47%	-94.88%	-68.69%	-101.57%	-102.73%	-39.04%	-48.07%	-60.81%	-74.68%	-43.42%
Return on Equity Simple (ROE_SIMPLE)	-57.38%	0.00%	-130.68%	-185.04%	-170.84%	0.00%	-31.57%	-38.03%	-47.35%	0.00%
Net Operating Profit after Tax (NOPAT)	-13	-31	-15	-16	-10	-11	-23	-24	-23	-32
NOPAT Margin	-128.63%	-290.68%	-196.38%	-174.99%	-66.30%	-81.61%	-199.63%	-255.17%	-217.82%	-273.28%
Net Nonoperating Expense Percent (NNEP)	-5.51%	-9.17%	-5.08%	-5.09%	-2.00%	-1.22%	-3.08%	-3.14%	-3.30%	-2.77%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-4.30%	-	-	-	-9.41%
Cost of Revenue to Revenue	0.00%	62.18%	8.33%	19.68%	7.91%	-25.91%	6.50%	14.78%	6.99%	-24.99%
SG&A Expenses to Revenue	92.01%	80.70%	120.29%	99.46%	69.44%	80.18%	120.69%	134.54%	123.24%	108.19%
R&D to Revenue	111.49%	147.56%	177.25%	172.76%	114.22%	127.97%	257.95%	314.68%	280.71%	374.72%
Operating Expenses to Revenue	283.76%	453.08%	372.21%	330.30%	186.80%	242.49%	378.69%	449.74%	404.18%	515.39%
Earnings before Interest and Taxes (EBIT)	-18	-43	-20	-21	-13	-14	-29	-31	-29	-41
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-17	-43	-20	-21	-13	-14	-30	-32	-31	-43
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.98	1.24	1.29	5.21	4.77	3.06	4.12	1.98	1.95	1.51
Price to Tangible Book Value (P/TBV)	2.33	1.24	1.29	5.21	4.77	3.06	4.12	1.98	1.95	1.51
Price to Revenue (P/Rev)	6.35	2.88	2.53	7.99	6.57	17.73	20.59	8.99	9.35	11.75
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	8.14	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	3.58	0.35	0.33	4.18	3.37	10.54	14.61	3.43	3.80	3.18
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	10.78	11.58	258.64	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	5.09	5.86	128.56	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.29	0.41	0.44	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.21	0.30	0.37	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.88	-1.00	-0.98	-1.32	-1.30	-1.20	-1.18	-1.48	-1.41	-1.17
Leverage Ratio	1.70	1.58	1.63	1.96	1.95	1.48	1.47	1.75	1.66	1.28
Compound Leverage Factor	1.76	1.61	1.69	2.13	1.95	1.48	1.47	1.75	1.66	1.28
Debt to Total Capital	22.56%	29.22%	30.66%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	5.95%	7.69%	4.68%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	16.61%	21.53%	25.98%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	77.44%	70.78%	69.34%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	-0.57	-0.42	-0.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	1.68	1.10	0.89	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	-0.42	-0.31	-0.30	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.77	-0.57	-0.48	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	2.27	1.50	1.22	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	-0.57	-0.42	-0.41	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-1.28	-3.99	-4.73	-3.70	-4.06	3.54	5.30	0.07	-0.04	1.54
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.61	5.00	5.36	2.42	2.35	5.45	5.08	4.75	5.50	7.81
Quick Ratio	5.20	4.63	4.88	2.23	2.14	5.25	4.83	4.53	5.21	7.57
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-22	-13	9.96	89	86	45	17	-58	-65	-62
Operating Cash Flow to CapEx	-1,096.49%	-2,151.79%	-3,478.31%	14,399.75%	-883.95%	-2,617.10%	-2,610.64%	-2,242.00%	-2,479.54%	-9,335.68%
Free Cash Flow to Firm to Interest Expense	-33.63	-16.42	12.26	50.05	0.00	0.00	0.00	0.00	0.00	-4,427.31
Operating Cash Flow to Interest Expense	-19.84	-16.12	-20.73	32.00	0.00	0.00	0.00	0.00	0.00	-2,560.64
Operating Cash Flow Less CapEx to Interest Expense	-21.65	-16.87	-21.33	31.78	0.00	0.00	0.00	0.00	0.00	-2,588.07
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.22	0.19	0.20	0.18	0.22	0.17	0.21	0.20	0.20	0.11
Accounts Receivable Turnover	2.46	2.45	2.65	2.23	3.98	5.64	7.45	8.18	106.19	61.29
Inventory Turnover	1.19	2.56	1.94	2.39	2.51	0.00	1.14	1.10	1.05	0.00
Fixed Asset Turnover	53.86	45.10	25.23	18.74	15.48	13.92	10.77	10.31	7.10	6.45
Accounts Payable Turnover	0.75	1.25	0.86	1.01	1.30	0.00	0.57	0.35	0.46	0.00
Days Sales Outstanding (DSO)	148.35	149.23	137.64	163.99	91.67	64.67	49.03	44.64	3.44	5.96
Days Inventory Outstanding (DIO)	307.40	142.52	188.03	152.71	145.31	0.00	319.90	332.06	346.07	0.00
Days Payable Outstanding (DPO)	483.80	291.61	425.34	361.20	281.23	0.00	635.16	1,046.99	793.13	0.00
Cash Conversion Cycle (CCC)	-28.04	0.14	-99.67	-44.50	-44.25	64.67	-266.23	-670.29	-443.63	5.96
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	19	-8.56	-9.58	-85	-78	-65	-50	-52	-35	-35
Invested Capital Turnover	3.04	122.50	13.51	-1.14	-1.44	-1.25	-1.69	-0.73	-0.81	-0.87
Increase / (Decrease) in Invested Capital	9.38	-18	-25	-105	-96	-56	-40	33	42	30
Enterprise Value (EV)	152	15	13	156	144	485	731	173	174	138
Market Capitalization	270	119	101	298	280	816	1,030	453	428	508
Book Value per Share	$4.00	$2.83	$2.29	$1.67	$1.68	$7.54	$5.02	$4.38	$4.09	$4.93
Tangible Book Value per Share	$3.39	$2.83	$2.29	$1.67	$1.68	$7.54	$5.02	$4.38	$4.09	$4.93
Total Capital	176	136	113	57	59	266	250	228	219	337
Total Debt	40	40	35	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	29	29	29	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-118	-105	-88	-143	-136	-331	-299	-280	-254	-371
Capital Expenditures (CapEx)	1.20	0.59	0.48	0.40	1.72	0.88	1.19	0.90	1.57	0.38
Debt-free, Cash-free Net Working Capital (DFCFNWC)	11	4.19	1.63	-44	-50	-50	-44	-47	-34	-37
Debt-free Net Working Capital (DFNWC)	168	149	124	98	86	282	255	233	220	334
Net Working Capital (NWC)	158	138	119	98	86	282	255	233	220	334
Net Nonoperating Expense (NNE)	5.54	13	6.08	6.99	2.53	2.65	5.96	6.64	6.44	9.73
Net Nonoperating Obligations (NNO)	-118	-105	-88	-143	-136	-331	-299	-280	-254	-371
Total Depreciation and Amortization (D&A)	0.50	-0.01	-0.14	0.08	0.08	-0.41	-0.27	-1.33	-1.47	-1.34
Debt-free, Cash-free Net Working Capital to Revenue	26.08%	10.11%	4.09%	-118.75%	-116.98%	-107.59%	-88.40%	-94.10%	-74.46%	-84.71%
Debt-free Net Working Capital to Revenue	396.84%	359.26%	311.89%	263.04%	202.87%	611.80%	510.06%	462.04%	480.73%	772.44%
Net Working Capital to Revenue	372.15%	333.96%	298.58%	263.04%	202.87%	611.80%	510.06%	462.04%	480.73%	772.44%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.49)	($1.16)	($0.56)	($0.61)	($0.33)	($0.32)	($0.55)	($0.58)	($0.54)	($0.65)
Adjusted Weighted Average Basic Shares Outstanding	37.34M	37.32M	37.49M	37.58M	38.34M	38.90M	52.91M	53.21M	54.45M	56.30M
Adjusted Diluted Earnings per Share	($0.49)	($1.16)	($0.56)	($0.61)	($0.33)	($0.32)	($0.55)	($0.58)	($0.54)	($0.65)
Adjusted Weighted Average Diluted Shares Outstanding	37.34M	37.32M	37.49M	37.58M	38.34M	38.90M	52.91M	53.21M	54.45M	56.30M
Adjusted Basic & Diluted Earnings per Share	$0.00	($1.16)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	34.08M	34.30M	34.30M	34.98M	35.31M	49.83M	52.08M	53.52M	68.25M	68.73M
Normalized Net Operating Profit after Tax (NOPAT)	-13	-31	-15	-16	-10	-11	-23	-24	-23	-32
Normalized NOPAT Margin	-128.63%	-290.68%	-196.38%	-174.99%	-66.30%	-81.61%	-199.63%	-255.17%	-217.82%	-273.28%
Pre Tax Income Margin	-183.98%	-412.53%	-275.47%	-251.73%	-82.96%	-99.91%	-250.63%	-325.27%	-278.99%	-356.48%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-26.82	-54.64	-25.06	-11.86	0.00	0.00	0.00	0.00	0.00	-2,949.64
NOPAT to Interest Expense	-19.45	-39.20	-18.58	-8.94	0.00	0.00	0.00	0.00	0.00	-2,261.95
EBIT Less CapEx to Interest Expense	-28.63	-55.39	-25.66	-12.08	0.00	0.00	0.00	0.00	0.00	-2,977.07
NOPAT Less CapEx to Interest Expense	-21.26	-39.95	-19.18	-9.16	0.00	0.00	0.00	0.00	0.00	-2,289.38
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.77%	-0.59%	-0.24%	-0.02%	-0.41%	-0.64%	-0.68%	-0.52%	-0.33%	-0.51%

Frequently Asked Questions About EyePoint Pharmaceuticals' Financials

When does EyePoint Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, EyePoint Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has EyePoint Pharmaceuticals' net income changed over the last 2 years?

EyePoint Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$130.87 million in 2024, rising from -$102.25 million in 2022. The previous period was -$70.80 million in 2023. Check out EyePoint Pharmaceuticals' forecast to explore projected trends and price targets.

What is EyePoint Pharmaceuticals's operating income?

EyePoint Pharmaceuticals's total operating income in 2024 was -$145.85 million, based on the following breakdown:

Total Gross Profit: $43.27 million
Total Operating Expenses: $189.13 million

How has EyePoint Pharmaceuticals revenue changed over the last 2 years?

Over the last 2 years, EyePoint Pharmaceuticals' total revenue changed from $41.40 million in 2022 to $43.27 million in 2024, a change of 4.5%.

How much debt does EyePoint Pharmaceuticals have?

EyePoint Pharmaceuticals' total liabilities were at $81.96 million at the end of 2024, a 7.8% decrease from 2023, and a 2.4% decrease since 2022.

How much cash does EyePoint Pharmaceuticals have?

In the past 2 years, EyePoint Pharmaceuticals' cash and equivalents has ranged from $95.63 million in 2022 to $281.26 million in 2023, and is currently $99.70 million as of their latest financial filing in 2024.

How has EyePoint Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, EyePoint Pharmaceuticals' book value per share changed from 2.83 in 2022 to 4.93 in 2024, a change of 74.4%.

Related Companies

This page (NASDAQ:EYPT) was last updated on 5/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

EyePoint Pharmaceuticals (EYPT) Financials

Frequently Asked Questions About EyePoint Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

EyePoint Pharmaceuticals (EYPT) Financials

Annual Income Statements for EyePoint Pharmaceuticals

Quarterly Income Statements for EyePoint Pharmaceuticals

Annual Cash Flow Statements for EyePoint Pharmaceuticals

Quarterly Cash Flow Statements for EyePoint Pharmaceuticals

Annual Balance Sheets for EyePoint Pharmaceuticals

Quarterly Balance Sheets for EyePoint Pharmaceuticals

Annual Metrics and Ratios for EyePoint Pharmaceuticals

Quarterly Metrics and Ratios for EyePoint Pharmaceuticals

Frequently Asked Questions About EyePoint Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools